Home > Insider Trading > Filing (0001209191-23-054913)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1907108	Lexeo Therapeutics Inc.	LXEO	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1361712	Otello Stampacchia	C/O Omega Funds 888 Boylston St., Suite 1111 Boston MA 02199	No	No	Yes	No
1652863	Anne-Mari Paster	C/O Omega Funds 888 Boylston Street, Suite 1111 Boston MA 02119	No	No	Yes	No
1722050	Claudio Nessi	C/O Omega Funds 888 Boylston Street, Suite 1111 Boston MA	No	No	Yes	No
1757917	Omega Fund Vi, L.p.	888 Boylston Street, Suite 1111 Boston MA 02199	No	No	Yes	No
1826584	Omega Fund Vi Gp Manager, Ltd.	888 Boylston Street, Suite 1111 Boston MA 02199	No	No	Yes	No
1826592	Omega Fund Vi Gp, L.p.	888 Boylston Street, Suite 1111 Boston MA 02199	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-11-07	1,415,865	$0.00	1,415,865	No	4	C	Direct
Common Stock	Acquisiton	2023-11-07	287,213	$0.00	1,703,078	No	4	C	Direct
Common Stock	Acquisiton	2023-11-07	454,545	$11.00	2,157,623	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A convertible preferred stock	Disposition	2023-11-07	14,999,999	$0.00	1,415,865	$0.00
Common Stock	Series B convertible preferred stock	Disposition	2023-11-07	2,615,533	$0.00	287,213	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
0			No	4	C	Direct

Footnotes

Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.
Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.